Alumis Inc. raised $259M in a upsized funding round to support its clinical-stage biopharmaceutical development.
PUBLIC · ALMSMar 07, 2024
Amount Raised
$259 Million
Round Type
Series C
Los AngelesBiotechnologyHealthcareHealth Care
Investors
Venture Capital Investors
Description
South San Francisco-based clinical-stage biopharmaceutical company Alumis Inc. closed its upsized Series C funding round after securing $259 million from venture capital investors.
Who to call at Alumis, and when
A new round usually means Alumis is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Alumis raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Alumis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alumis. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Alumis
Location
Los Angeles, California, United States
About
A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alumis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.